Juan Carlos Cámara

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Development and Validation of a Prognostic Nomogram for Terminally Ill Cancer Patients

Jaime Feliú, Ana M. Jiménez-Gordo, Rosário Madero et al. · JNCI Journal of the National Cancer Institute · 2011 · 98 citations · Full text

Medicine, Oncology, Palliative Care +12

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Jean‐François Emile, Catherine Julié, Karine Le Malicot et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Immunology, Oncology +17

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, M. Martínez-Villacampa et al. · Annals of Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +12

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

Patricia Llovet, Javier Sastre, Julián Sanz‐Ortega et al. · Molecular Diagnosis & Therapy · 2015 · 26 citations

Medicine, Molecular Medicine, Oncology +14